#ariba_ref_name	ref_name	gene	var_only	flag	reads	cluster	ref_len	ref_base_assembled	pc_ident	ctg	ctg_len	ctg_cov	known_var	var_type	var_seq_type	known_var_change	has_known_var	ref_ctg_change	ref_ctg_effect	ref_start	ref_end	ref_nt	ctg_start	ctg_end	ctg_nt	smtls_total_depth	smtls_nts	smtls_nts_depth	var_description	free_text
16S.rDNA_WHO_F_01361c	16S.rDNA_WHO_F_01361c	0	1	659	10170	16S	1529	1529	99.87	16S.l15.c4.ctg.1	1989	502.0	0	.	n	.	0	A69G	SNP	69	69	A	307	307	G	535	G,A	522,2	.	.
16S.rDNA_WHO_F_01361c	16S.rDNA_WHO_F_01361c	0	1	659	10170	16S	1529	1529	99.87	16S.l15.c4.ctg.1	1989	502.0	0	.	n	.	0	C1450T	SNP	1450	1450	C	1688	1688	T	556	T,C	530,1	.	.
16S.rDNA_WHO_F_01361c	16S.rDNA_WHO_F_01361c	0	1	659	10170	16S	1529	1529	99.87	16S.l15.c4.ctg.1	1989	502.0	1	SNP	n	C1184T	0	.	.	1184	1184	C	1422	1422	C	606	C	600	16S.rDNA_WHO_F_01361c:0:1:C1184T:16S.1184T:E coli C1192T. Resistance to Spectinomycin	.
16S.rDNA_WHO_F_01361c	16S.rDNA_WHO_F_01361c	0	1	659	10170	16S	1529	1529	99.87	16S.l15.c4.ctg.1	1989	502.0	0	HET	.	.	.	G537GC	.	537	537	G	775	775	G	600	GC,G	435,143	.	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	19522	23S	2890	2890	99.9	23S.l15.c4.ctg.1	3594	538.7	0	.	n	.	0	G1337A	SNP	1337	1337	G	1666	1666	A	661	A,G	648,2	.	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	19522	23S	2890	2890	99.9	23S.l15.c4.ctg.1	3594	538.7	0	.	n	.	0	T1971C	SNP	1971	1971	T	2300	2300	C	610	C,T,A	590,1,1	.	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	19522	23S	2890	2890	99.9	23S.l15.c4.ctg.1	3594	538.7	1	SNP	n	C2597T	1	C2597T	SNP	2597	2597	C	2926	2926	T	607	T,C	597,1	23S.rDNA_WHO_F_01358c:0:1:C2597T:23S.2597T :E coli C2611T. Low-level resistance to Azithromycin	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	19522	23S	2890	2890	99.9	23S.l15.c4.ctg.1	3594	538.7	1	SNP	n	A2045G	0	.	.	2045	2045	A	2374	2374	A	628	A	617	23S.rDNA_WHO_F_01358c:0:1:A2045G:23S.2045G:E coli A2059G. High-level resistance to Azithromycin	.
folP.WHO_W_01420c	folP.WHO_W_01420c	1	1	539	1400	folP	852	852	99.88	folP.l15.c4.ctg.1	1565	88.8	0	.	p	.	0	E151K	NONSYN	451	453	GAA	740	742	AAA	138;136;135	A,G;A;A	134,1;135;134	.	.
folP.WHO_W_01420c	folP.WHO_W_01420c	1	1	539	1400	folP	852	852	99.88	folP.l15.c4.ctg.1	1565	88.8	1	SNP	p	R228S	1	.	.	682	684	AGC	971	973	AGC	132;132;133	A;G;C	130;130;129	folP.WHO_W_01420c:1:1:R228S:folP.228S:Resistance to sulphonamides	.
gyrA.WHO_F_00668c	gyrA.WHO_F_00668c	1	1	27	3958	gyrA	2751	2751	100.0	gyrA.l15.c4.ctg.1	3265	120.0	1	SNP	p	S91F	0	.	.	271	273	TCC	524	526	TCC	149;152;151	T;C;C	146;147;146	gyrA.WHO_F_00668c:1:1:S91F:gyrA.91F:Resistance to fluoroquinolones	.
gyrA.WHO_F_00668c	gyrA.WHO_F_00668c	1	1	27	3958	gyrA	2751	2751	100.0	gyrA.l15.c4.ctg.1	3265	120.0	1	SNP	p	D95N	0	.	.	283	285	GAC	536	538	GAC	153;154;155	G,T;A;C,T	148,1;146;151,1	gyrA.WHO_F_00668c:1:1:D95N:gyrA.95N:Resistance to fluoroquinolones	.
gyrA.WHO_F_00668c	gyrA.WHO_F_00668c	1	1	27	3958	gyrA	2751	2751	100.0	gyrA.l15.c4.ctg.1	3265	120.0	1	SNP	p	D95G	0	.	.	283	285	GAC	536	538	GAC	153;154;155	G,T;A;C,T	148,1;146;151,1	gyrA.WHO_F_00668c:1:1:D95G:gyrA.95G:Resistance to fluoroquinolones	.
mtrR.WHO_Y_01506	mtrR.WHO_Y_01506	1	1	27	1186	mtrR	633	633	100.0	mtrR.l15.c4.ctg.1	1233	95.0	1	SNP	p	G45D	0	.	.	133	135	GGC	403	405	GGC	138;136;136	G,C;G;C,T	137,1;134;132,1	mtrR.WHO_Y_01506:1:1:G45D:mtrR.45D:Increased efflux of antimicrobials, e.g. macrolides and b-lactam antimicrobials, that are substrates of the MtrCDE efflux pump	.
mtrR_promoter.WHO_F	mtrR_promoter.WHO_F	0	0	531	670	mtrR_promoter	250	250	99.6	mtrR_promoter.l15.c4.ctg.1	977	67.8	0	.	n	.	0	A197.	DEL	197	197	A	565	565	A	149	A	148	.	.
parC.WHO_M_00204c	parC.WHO_M_00204c	1	1	27	3298	parC	2304	2304	99.91	parC.l6.c30.ctg.1	2910	112.2	1	SNP	p	D86N	0	.	.	256	258	GAC	551	553	GAC	127;128;127	G;A;C	127;124;126	parC.WHO_M_00204c:1:1:D86N:parC.86N:Resistance to fluoroquinolones	.
parC.WHO_M_00204c	parC.WHO_M_00204c	1	1	27	3298	parC	2304	2304	99.91	parC.l6.c30.ctg.1	2910	112.2	1	SNP	p	S87I	0	.	.	259	261	AGT	554	556	AGT	127;126;125	A;G;T	126;126;124	parC.WHO_M_00204c:1:1:S87I:parC.87I:Resistance to fluoroquinolones	.
parC.WHO_M_00204c	parC.WHO_M_00204c	1	1	27	3298	parC	2304	2304	99.91	parC.l6.c30.ctg.1	2910	112.2	1	SNP	p	S87W	0	.	.	259	261	AGT	554	556	AGT	127;126;125	A;G;T	126;126;124	parC.WHO_M_00204c:1:1:S87W:parC.87W:Resistance to fluoroquinolones	.
parC.WHO_M_00204c	parC.WHO_M_00204c	1	1	27	3298	parC	2304	2304	99.91	parC.l6.c30.ctg.1	2910	112.2	1	SNP	p	S87R	0	.	.	259	261	AGT	554	556	AGT	127;126;125	A;G;T	126;126;124	parC.WHO_M_00204c:1:1:S87R:parC.87R:Resistance to fluoroquinolones	.
parC.WHO_M_00204c	parC.WHO_M_00204c	1	1	27	3298	parC	2304	2304	99.91	parC.l6.c30.ctg.1	2910	112.2	1	SNP	p	S88P	0	.	.	262	264	TCC	557	559	TCC	125;127;129	T;C;C	124;127;128	parC.WHO_M_00204c:1:1:S88P:parC.88P:Resistance to fluoroquinolones	.
parE.WHO_F_01528c	parE.WHO_F_01528c	1	1	27	2886	parE	1986	1986	100.0	parE.l15.c4.ctg.1	2611	109.4	1	SNP	p	G410V	0	.	.	1228	1230	GGC	1561	1563	GGC	146;144;141	G;G;C	144;140;137	parE.WHO_F_01528c:1:1:G410V:parE.410V:Resistance to fluoroquinolones	.
penA.9.001	penA.9.001	1	1	27	2658	penA	1749	1749	100.0	penA.l6.c4.ctg.1	2420	108.9	1	SNP	p	A311V	0	.	.	931	933	GCA	1260	1262	GCA	148;148;150	G,T;C;A	145,1;147;147	penA.9.001:1:1:A311V:penA.311V:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.9.001	penA.9.001	1	1	27	2658	penA	1749	1749	100.0	penA.l6.c4.ctg.1	2420	108.9	1	SNP	p	I312M	0	.	.	934	936	ATC	1263	1265	ATC	152;156;156	A,C;T;C	150,1;151;153	penA.9.001:1:1:I312M:penA.312M:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.9.001	penA.9.001	1	1	27	2658	penA	1749	1749	100.0	penA.l6.c4.ctg.1	2420	108.9	1	SNP	p	V316P	0	.	.	946	948	GTG	1275	1277	GTG	156;151;154	G;T;G	152;148;150	penA.9.001:1:1:V316P:penA.316P:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.9.001	penA.9.001	1	1	27	2658	penA	1749	1749	100.0	penA.l6.c4.ctg.1	2420	108.9	1	SNP	p	V316T	0	.	.	946	948	GTG	1275	1277	GTG	156;151;154	G;T;G	152;148;150	penA.9.001:1:1:V316T:penA.316T:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.9.001	penA.9.001	1	1	27	2658	penA	1749	1749	100.0	penA.l6.c4.ctg.1	2420	108.9	1	SNP	p	T484S	0	.	.	1450	1452	ACC	1779	1781	ACC	110;108;105	A;C;C	100;104;103	penA.9.001:1:1:T484S:penA.483S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.9.001	penA.9.001	1	1	27	2658	penA	1749	1749	100.0	penA.l6.c4.ctg.1	2420	108.9	1	SNP	p	A502V	0	.	.	1504	1506	GCG	1833	1835	GCG	100;98;96	G;C;G	89;81;91	penA.9.001:1:1:A502V:penA.501V:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.9.001	penA.9.001	1	1	27	2658	penA	1749	1749	100.0	penA.l6.c4.ctg.1	2420	108.9	1	SNP	p	A502P	0	.	.	1504	1506	GCG	1833	1835	GCG	100;98;96	G;C;G	89;81;91	penA.9.001:1:1:A502P:penA.501P:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.9.001	penA.9.001	1	1	27	2658	penA	1749	1749	100.0	penA.l6.c4.ctg.1	2420	108.9	1	SNP	p	G543S	0	.	.	1627	1629	GGC	1956	1958	GGC	103;101;98	G;G;C	100;98;96	penA.9.001:1:1:G543S:penA.542S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.9.001	penA.9.001	1	1	27	2658	penA	1749	1749	100.0	penA.l6.c4.ctg.1	2420	108.9	1	SNP	p	G546S	0	.	.	1636	1638	GGC	1965	1967	GGC	88;89;89	G;G;C	85;88;85	penA.9.001:1:1:G546S:penA.545S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.9.001	penA.9.001	1	1	27	2658	penA	1749	1749	100.0	penA.l6.c4.ctg.1	2420	108.9	1	SNP	p	L552S	0	.	.	1654	1656	CTG	1983	1985	CTG	74;74;73	C,G;TG,TGG;G	59,4;52,1;57	penA.9.001:1:1:L552S:penA.551S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
ponA.WHO_G_00106	ponA.WHO_G_00106	1	1	27	3976	ponA	2397	2397	100.0	ponA.l15.c4.ctg.1	3236	122.0	1	SNP	p	L421P	1	.	.	1261	1263	CCG	1686	1688	CCG	151;150;150	C;C;G	138;148;143	ponA.WHO_G_00106:1:1:L421P:ponA.421P:High-level chromosomally-mediated penicillin resistance	.
porA.NCCP11945	porA.NCCP11945	1	0	531	1822	porA	1146	1146	99.65	porA.l6.c4.ctg.1	1684	106.5	0	.	p	.	0	M83fs	FSHIFT	247	247	A	494	494	C	105	C	100	.	.
porB1a.WHO_F_02106	porB1a.WHO_F_02106	1	0	528	246	porB1a	984	218	90.37	porB1a.l6.c30.ctg.2	330	20.1	0	.	p	.	0	V258L	NONSYN	772	774	GTA	6	8	TTA	41;43;43	T;T;A	16;18;18	.	.
porB1a.WHO_F_02106	porB1a.WHO_F_02106	1	0	528	246	porB1a	984	218	90.37	porB1a.l6.c30.ctg.2	330	20.1	0	.	p	.	0	Y273H	NONSYN	817	819	TAT	51	53	CAT	32;30;28	C;A;T	27;28;28	.	.
porB1a.WHO_F_02106	porB1a.WHO_F_02106	1	0	528	246	porB1a	984	218	90.37	porB1a.l6.c30.ctg.2	330	20.1	0	.	p	.	0	D274S	NONSYN	820	822	GAT	54	56	AGT	28;28;28	A;G;T	28;28;25	.	.
porB1a.WHO_F_02106	porB1a.WHO_F_02106	1	0	528	246	porB1a	984	218	90.37	porB1a.l6.c30.ctg.2	330	20.1	0	.	p	.	0	N277Y	NONSYN	829	831	AAC	63	65	TAC	28;28;29	T;A;C	28;28;28	.	.
porB1a.WHO_F_02106	porB1a.WHO_F_02106	1	0	528	246	porB1a	984	218	90.37	porB1a.l6.c30.ctg.2	330	20.1	0	.	p	.	0	R307V	NONSYN	919	921	AGA	153	155	GTA	13;14;14	G;T;A	13;14;14	.	.
porB1a.WHO_F_02106	porB1a.WHO_F_02106	1	0	528	246	porB1a	984	218	90.37	porB1a.l6.c30.ctg.2	330	20.1	0	.	p	.	0	T311A	NONSYN	931	933	ACA	165	167	GCA	14;14;15	G;C;A	14;14;15	.	.
porB1a.WHO_F_02106	porB1a.WHO_F_02106	1	0	528	246	porB1a	984	218	90.37	porB1a.l6.c30.ctg.2	330	20.1	0	.	p	.	0	E312D	NONSYN	934	936	GAA	168	170	GAC	16;15;15	G;A;C	15;15;15	.	.
porB1a.WHO_F_02106	porB1a.WHO_F_02106	1	0	528	246	porB1a	984	218	90.37	porB1a.l6.c30.ctg.2	330	20.1	0	.	p	.	0	F314I	NONSYN	940	942	TTC	174	176	ATC	16;16;16	A;T;C	16;16;16	.	.
porB1a.WHO_F_02106	porB1a.WHO_F_02106	1	0	528	246	porB1a	984	218	90.37	porB1a.l6.c30.ctg.2	330	20.1	0	.	p	.	0	A316S	NONSYN	946	948	GCG	180	182	TCG	16;14;14	T;C;G	16;14;14	.	.
porB1a.WHO_F_02106	porB1a.WHO_F_02106	1	0	528	246	porB1a	984	218	90.37	porB1a.l6.c30.ctg.2	330	20.1	0	.	p	.	0	V318A	NONSYN	952	954	GTC	186	188	GCC	12;12;12	G;C;C	12;12;12	.	.
porB1a.WHO_F_02106	porB1a.WHO_F_02106	1	0	528	246	porB1a	984	218	90.37	porB1a.l6.c30.ctg.2	330	20.1	0	.	p	.	0	G319S	NONSYN	955	957	GGC	189	191	AGC	12;12;12	A;G;C	12;12;12	.	.
porB1a.WHO_F_02106	porB1a.WHO_F_02106	1	0	528	246	porB1a	984	218	90.37	porB1a.l6.c30.ctg.2	330	20.1	0	.	p	.	0	G320A	NONSYN	958	960	GGT	192	194	GCC	12;12;12	G;C;C	12;12;12	.	.
porB1a.WHO_F_02106	porB1a.WHO_F_02106	1	0	528	246	porB1a	984	218	90.37	porB1a.l6.c30.ctg.2	330	20.1	0	.	p	.	0	G322V	NONSYN	964	966	GGT	198	200	GTT	11;11;11	G;T;T	11;11;11	.	.
porB1b.WHO_V_02265c	porB1b.WHO_V_02265c	1	1	539	2012	porB1b	1047	1047	99.24	porB1b.l15.c4.ctg.1	1440	137.2	0	.	p	.	0	N38E	NONSYN	112	114	AAT	370	372	GAA	151;153;153	G;A;A	148;150;151	.	.
porB1b.WHO_V_02265c	porB1b.WHO_V_02265c	1	1	539	2012	porB1b	1047	1047	99.24	porB1b.l15.c4.ctg.1	1440	137.2	0	.	p	.	0	N134D	NONSYN	400	402	AAT	658	660	GAT	166;169;170	G;A;T	161;161;165	.	.
porB1b.WHO_V_02265c	porB1b.WHO_V_02265c	1	1	539	2012	porB1b	1047	1047	99.24	porB1b.l15.c4.ctg.1	1440	137.2	0	.	p	.	0	P175S	NONSYN	523	525	CCA	781	783	TCA	154;155;156	T;C;A	147;152;153	.	.
porB1b.WHO_V_02265c	porB1b.WHO_V_02265c	1	1	539	2012	porB1b	1047	1047	99.24	porB1b.l15.c4.ctg.1	1440	137.2	0	.	p	.	0	D212N	NONSYN	634	636	GAT	892	894	AAT	154;155;154	A;A;T	153;155;148	.	.
porB1b.WHO_V_02265c	porB1b.WHO_V_02265c	1	1	539	2012	porB1b	1047	1047	99.24	porB1b.l15.c4.ctg.1	1440	137.2	0	.	p	.	0	A218V	NONSYN	652	654	GCC	910	912	GTC	139;139;137	G;TCCCC,TCCC;C	136;134,1;135	.	.
porB1b.WHO_V_02265c	porB1b.WHO_V_02265c	1	1	539	2012	porB1b	1047	1047	99.24	porB1b.l15.c4.ctg.1	1440	137.2	0	.	p	.	0	E328V	NONSYN	982	984	GAA	1240	1242	GTA	153;155;155	G;T;A	152;148;155	.	.
porB1b.WHO_V_02265c	porB1b.WHO_V_02265c	1	1	539	2012	porB1b	1047	1047	99.24	porB1b.l15.c4.ctg.1	1440	137.2	1	SNP	p	G120K	1	.	.	358	360	AAG	616	618	AAG	165;167;167	A;A;G	162;163;162	porB1b.WHO_V_02265c:1:1:G120K:porB1b.120K:G101K. Mediates decreased permeability of antimicrobials through the porin PorB1b	.
porB1b.WHO_V_02265c	porB1b.WHO_V_02265c	1	1	539	2012	porB1b	1047	1047	99.24	porB1b.l15.c4.ctg.1	1440	137.2	1	SNP	p	D121N	0	.	.	361	363	GAC	619	621	GAC	168;165;161	G;A;C	165;156;156	porB1b.WHO_V_02265c:1:1:D121N:porB1b.121N:A102N. Mediates decreased permeability of antimicrobials through the porin PorB1b	.
porB1b.WHO_V_02265c	porB1b.WHO_V_02265c	1	1	539	2012	porB1b	1047	1047	99.24	porB1b.l15.c4.ctg.1	1440	137.2	1	SNP	p	A121D	1	.	.	361	363	GAC	619	621	GAC	168;165;161	G;A;C	165;156;156	porB1b.WHO_V_02265c:1:1:A121D:porB1b.121D:A102D. Mediates decreased permeability of antimicrobials through the porin PorB1b	.
rpoB.WHO_F_02153c	rpoB.WHO_F_02153c	1	1	539	7042	rpoB	4179	4179	99.98	rpoB.l15.c17.ctg.1	4823	144.9	1	SNP	p	H553N	1	H553N	NONSYN	1657	1659	CAT	1997	1999	AAT	174;172;173	A;A;T	172;170;169	rpoB.WHO_F_02153c:1:1:H553N:rpoB.553N:H552N. High-level resistance to Rifampicin	.
rpsJ.WHO_Y_02241	rpsJ.WHO_Y_02241	1	1	27	860	rpsJ	312	312	100.0	rpsJ.l15.c17.ctg.1	1020	83.0	1	SNP	p	V57M	1	.	.	169	171	ATG	558	560	ATG	152;150;150	A;T;G	150;148;147	rpsJ.WHO_Y_02241:1:1:V57M:rpsJ.57M:Chromosomally-mediated resistance to tetracyclines	.
